Segment (Tables)

12 Months Ended

Dec. 31, 2024

The Company’s sole reportable segment generates revenue by providing research and development services.


	Year Ended December 31,
	2024		2023		2022
Revenue	$	61	$	130	$	84,683
Operating expenses:
Research and development
Technical operations	63,419		64,393		55,412
Clinical operations	39,783		31,802		19,191
Research activities	37,772		53,567		57,328
Facilities and technology	26,342		25,636		25,081
Operations management	4,287		7,547		2,176
Total research and development expenses	171,603		182,945		159,188
General and administrative
Business support	33,973		47,428		84,500
Corporate expenses and outside services	14,450		15,575		27,717
Facilities and technology	3,618		3,980		5,090
Total general and administrative expenses	52,041		66,983		117,307
Other operating income, net	(3,309)		(2,790)		(4,754)
Acquired in-process research and development	87,184		—		—
Impairment of long-lived assets	51,297		—		—
Total operating expenses	358,816		247,138		271,741
Loss from operations	(358,755)		(247,008)		(187,058)
Interest income, net	24,068		23,453		7,053
Other income, net	4,694		1,846		1,887
Impairment of other investments	(13,001)		(12,923)		(5,000)
Total other income, net	15,761		12,376		3,940
Net loss	$	(342,994)	$	(234,632)	$	(183,118)